Navigation
banner

Infectious Diseases Summit

2017-11-182018-03-282018-02-28
EARLY BIRD DISCOUNT! Register by Feb 28, 2018 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


The 2018 agenda is currently being formed.

Please come back and visit this page for updates.

Below is the speaker list from 2017.

PLENARY KEYNOTE SPEAKERS
Heinz Feldmann

Heinz Feldmann
Chief, Laboratory of Virology & Disease Modeling and Transmission
NIAID, NIH
Heinz Feldmann
Chief, Laboratory of Virology & Disease Modeling and Transmission
NIAID, NIH
 
About Speaker:

Heinz Feldmann was born in Lippstadt, Germany, in 1959. He graduated from Medical School in 1987 (MD) and received his PhD in 1988 both from the University of Marburg, Germany. His postdoctoral research was conducted in the field of virology (filoviruses and hantaviruses) at the Institute of Virology, University of Marburg, Germany, and the Special Pathogens Branch at the Centers for Disease Control and Prevention in Atlanta, U.S.A, where he held a fellowship from the ‘National Research Council’. Following his postdoctoral training he held the position of an assistant and associate professor, with the Institute of Virology at the University of Marburg, Germany. During this time he was trained as an infectious disease specialist with focus on laboratory diagnostics. From 1999-2008, Heinz Feldmann held the position of Chief, Special Pathogens Program of the National Microbiology Laboratory, Public Health Agency of Canada. Since 2008, he is the Chief, Laboratory of Virology at the Rocky Mountain Laboratories (RML), DIR NIAID, NIH, and the Chief Scientist of the RML BSL4 Laboratories. In addition, he is an Associate Professor with the Department of Medical Microbiology, University of Manitoba. Heinz Feldmann is the laboratory expert on high containment viruses (BSL4) and serves as a consultant on viral hemorrhagic fevers and related pathogens for the World Health Organization and, thus, has field experience and expertise in outbreak management. His professional interest is in the pathogenesis and transmission of hemorrhagic fever viruses, such as filoviruses, arenaviruses and bunyaviruses, and other special viral pathogens (high containment, BSL3 and BSL4), and the development of countermeasures against those pathogens. Heinz Feldmann’s scientific contribution includes over 330 scientific publications, 6 patents and over 220 invited lectures at conferences and seminars worldwide. Heinz Feldmann was awarded with several honors including the ‘Löffler-Frosch Award’ from the German Society for Virology (DGV), the ‘Dalrymple/Young Award’ by the American Committee on Arthropod-Borne Viruses (ACAV), and Research Merit Awards from the Public Health Agency of Canada (PHAC) and the National Institute of Allergy and Infectious Diseases (NIAID).

Michael Osterholm

Michael Osterholm
Regents Professor & Director, Center for Infectious Disease Research and Policy
University of Minnesota
Michael Osterholm
Regents Professor & Director, Center for Infectious Disease Research and Policy
University of Minnesota
 
About Speaker:

Dr. Osterholm is Regents Professor, McKnight Presidential Endowed Chair in Public Health, the director of the Center for Infectious Disease Research and Policy (CIDRAP), Distinguished Teaching Professor in the Division of Environmental Health Sciences, School of Public Health, a professor in the Technological Leadership Institute, College of Science and Engineering, and an adjunct professor in the Medical School, all at the University of Minnesota. In addition, Dr. Osterholm is a member of the National Academy of Medicine (NAM) and the Council of Foreign Relations. In June 2005 Dr. Osterholm was appointed to the newly established National Science Advisory Board on Biosecurity. He served in that role until 2014.
From 2001 through early 2004, Dr. Osterholm, in addition to his role at CIDRAP, served as a Special Advisor to then–HHS Secretary Tommy G. Thompson on issues related to bioterrorism and public health preparedness. Dr. Osterholm is the author of “Deadliest Enemies: Our War Against Killer Germs (Little, Brown and Company), which will be published March 14, 2017.

David Vaughn

David Vaughn
Senior Vaccine Development Leader for Influenza and Dengue Vaccines, GSK Vaccines Research and Development
GSK
David Vaughn
Senior Vaccine Development Leader for Influenza and Dengue Vaccines, GSK Vaccines Research and Development
GSK
 
About Speaker:

David W. Vaughn, M.D., M.P.H. joined GSK Vaccines in 2007 with roles as the Clinical Lead for Pandemic Influenza Vaccines, Head of Global Vaccines Clinical Laboratories, Head of External R&D, North America, and currently as the Senior Vaccine Development Leader for Influenza and Dengue Vaccines also working in support of GSK’s proposal to establish a Biopreparedness Organization. This follows a 21-year career with the U.S. Army where he served as the Chief of the Department of Pediatrics in Nurnberg, Germany, Chief of the Department of Virology at the Armed Forces Research of Medical Sciences in Bangkok, Thailand and the Chief of the Department of Virus Diseases, Walter Reed Army Institute of Research leading efforts to develop vaccines against dengue, Japanese encephalitis, hepatitis E, and adenovirus. His final position in the military was as the Director of the U.S. Military Infectious Diseases Research Program. Dr. Vaughn holds B.A. degrees in Chemistry and Psychology from Seattle Pacific University, an M.D. degree from St. Louis University School of Medicine, Pediatrics certification following training at Indiana University School of Medicine, and an M.P.H. from the Johns Hopkins University School of Public Health and Hygiene.

PLENARY SPEAKERS
Kevin Gilligan

Kevin Gilligan
Senior Scientific Advisor
ClinicalRM
Kevin Gilligan
Senior Scientific Advisor
ClinicalRM
 
About Speaker:

Kevin J. Gilligan, Ph.D. is a virologist and emerging disease expert with over 30 years of experience in academia, government and industry developing vaccines, drugs and diagnostics to address public health issues related to global emerging disease.  Dr. Gilligan earned his Ph.D. in the Dept. pf Microbiology and Immunology at the University of North Carolina at Chapel Hill in 1990.  As a National Research Council Fellow working at Ft. Detrick, Dr. Gilligan was the first to demonstrate acquired immunity to Ebola virus via vaccination in a guinea pig animal model.  Dr. Gilligan recently left HHS/BARDA (U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority), where he was Branch Chief for drugs and therapeutics in the Influenza division. Dr. Gilligan has since joined ClinicalRM as Senior Scientific Advisor.

Brent Korba

Brent Korba
Professor
Georgetown University
Brent Korba
Professor
Georgetown University
 
About Speaker:

Dr. Korba has been a faculty member of the Department of Microbiology and Immunology in the Georgetown University Medical center since 1984. His expertise lies in the field of early stage pre-clinical drug discovery, utilizing enzymatic and tissue culture-based assays, as well as pre-clinical animal models. He has conducted antiviral testing contracts for the NIAID, NIH since 1990. His specific areas of focus are Hepatitis B and Noroviruses (current), as well as Hepatitis C. Dr. Korba has published over 115 peer-reviewed papers, 18 book chapters and 63 conference abstracts. He also holds several patents for the use of antiviral compounds. Dr. Korba is an active consultant in the pharmaceutical field, and has been a member of several scientific advisory boards for various companies. He is an ad-hoc reviewer and has been an editorial board member for a number of scientific journals, as well as grant study sections for the NIH and American Cancer Society.

Joseph Larsen

Joseph Larsen
Director (acting), CBRN Medical Countermeasures
BARDA, HHS
Joseph Larsen
Director (acting), CBRN Medical Countermeasures
BARDA, HHS
 
About Speaker:

Dr. Larsen is acting Director of the Division of CBRN Medical Countermeasures within the Biomedical Advanced Research Development Authority (BARDA). In that role, he oversees a $2.8B fund for the development and procurement of medical products for use during public health emergencies.  He is also the BARDA lead for the BARDA’s work on combating antibiotic resistant bacteria and is an executive member of CARB-X, a novel $450M public private partnership focused on promoting innovation in antibacterial drug development.  Dr. Larsen has been actively involved in discussing potential reforms to the economic incentive structures for antibacterial drug development.  Previously Dr. Larsen served as Deputy Director of BARDA’s CBRN Division.  From 2010-2014, Joe served as Chief of the Broad Spectrum Antimicrobials program at BARDA.   The goal of BARDA’s Broad Spectrum Antimicrobials program is to develop additional antimicrobial treatment options needed to counter the growing threat of antimicrobial resistance. In that role, he oversaw a portfolio of approximately $1.2B in programs that support the development of novel antibacterial and antiviral drugs. Dr. Larsen also serves as the BARDA representative on the U.S. Transatlantic Task Force on Antimicrobial Resistance. Dr. Larsen received his PhD in Microbiology from the Uniformed Services University of the Health Sciences and his BA with honors from the University of Kansas. 

Tyler Merkeley

Tyler Merkeley
Program Manager, CARB-X
BARDA, HHS
Tyler Merkeley
Program Manager, CARB-X
BARDA, HHS
 
About Speaker:

Tyler Merkeley MS, MBA, PMP, is the co-founder of CARB-X and serves as the Biomedical Advanced Research and Development Authority’s (BARDA) CARB-X Program Manager. He joined BARDA in 2009 as a Health Scientist to accelerate the advanced research and development, procurement, stockpile and sustainment of medical countermeasures (MCM) against biological, chemical, radiological, and nuclear (CBRN) agents under Project BioShield.  During his tenure at BARDA he has led the smallpox antiviral procurement, BARDA’s Total Life Cycle Costs containment initiative, designed and launched HHS’s Combating Antibiotic Resistant Bacteria (CARB) Accelerator [CARB-X], managed BARDA’s 1st agreement using Other Transaction Authority (OTA) and served as the Acting Chief of Staff for BARDA.

Jean-Pierre Paccaud

Jean-Pierre Paccaud
Director, Business Development
GARDP (Global Antibiotic R&D Partnership)
Jean-Pierre Paccaud
Director, Business Development
GARDP (Global Antibiotic R&D Partnership)
 
About Speaker:

Dr Paccaud is responsible for the business development and corporate strategy of GARDP, an initiative he contributed to created within DNDi. Previously he was responsible since 2007 for DNDi’s business development activities, including opportunity identification, contract structure and negotiations, and alliance management.

Dr Paccaud also notably founded and led Athelas SA, a startup company active in the field of anti-bacterial drug discovery, until its merger with Merlion Pharmaceuticals. Before taking on entrepreneurial challenges in industry, Dr Paccaud spent more than 15 years in academia, working in immunology, diabetes, and cell biology.

Trained as a molecular and cellular biologist, Jean-Pierre Paccaud completed his post-doctoral studies at the University of California at Berkeley, and earned his PhD at the University of Geneva School of Medicine.

Antiviral Drugs Research & Development 2017
DISTINGUISHED SPEAKERS
Donald Alcendor

Donald Alcendor
Associate Professor
Meharry Medical College
Donald Alcendor
Associate Professor
Meharry Medical College
 
About Speaker:

Donald Alcendor, PhD is an Associate Professor at Meharry Medical College and an Adjunct Associate Professor at Vanderbilt University Medical Center. Dr. Alcendor completed his graduate studies at University of California, Davis in Molecular Virology.  He completed his post-graduate studies at the NIH and Johns Hopkins University, in Baltimore Maryland in departments of Molecular Virology and Viral Oncology respectively.  Dr. Alcendor is the first to investigate the infectivity of human retinal pericytes for HCMV and their potential role in viral dissemination in the inner blood retinal barrier (IBRB) and the concomitant implications for CMV-associated ocular disease. Dr. Alcendor’s lab utilizes a tri-cell culture model system of the neurovascular unit (NVU) within the IBRB developed with primary human cells that are separately cultivated in a single source medium and infected with low passaged clinical isolates of HCMV from newborns at low multiplicities of infection to mimic human physiological conditions. He finds that retinal pericytes within the IBRB are most permissive for HCMV infection when compared retinal endothelial cells and Müller cells and are involved in the production of proinflammatory and angiogenic cytokines.

There are similarities between Zika virus and Cytomegalovirus ocular pathology.  Dr. Alcendor has recently expanded his studies to develop a pathogenic model and therapeutic intervention for Zika virus induced ocular disease.  DWK-M1 is a novel antiviral that can effectively inhibit Zika virus replication and suppress Zika virus induced inflammation in vitro. DWK-M1 is a non-toxic compound, stable at room temperature that can penetrate target cells.  DWK-M1 has unique features of a therapeutic antiviral for ZIKV associated ocular disease. Currently there is no specific treatment or vaccine for Zika virus infection.  This addresses an urgent unmet medical need for efficacious therapeutics for Zika virus.

Santanu Bose

Santanu Bose
Professor
Washington State University
Santanu Bose
Professor
Washington State University
 
About Speaker:

Dr. Bose is currently a faculty member in the Washington State University College of Veterinary Medicine. Before moving to Washington State in 2014, Dr. Bose was a faculty member of the Department of Microbiology and Immunology in the University of Texas Health Science Center Medical School. His research is focused on understanding various aspect of innate immune response against respiratory viruses like human respiratory syncytial virus (RSV), influenza A virus and parainfluenza viruses. Particularly he is interested in elucidating the mechanism regulating innate antiviral and inflammatory response, which play a critical role in host defense against respiratory viruses. Dr. Bose has published widely in top quality research journals and holds US patents. Dr. Bose is in the editorial board and serves as an academic editor for numerous per-reviewed research journals and more recently served as a regular member of NIH study section.

John Burnett

John Burnett
Assistant Professor, Molecular and Cellular Biology, Beckman Research Institute
City of Hope
John Burnett
Assistant Professor, Molecular and Cellular Biology, Beckman Research Institute
City of Hope
 
About Speaker:

John Burnett, Ph.D., is Assistant Professor in Molecular and Cellular Biology at Beckman Research Institute of City of Hope. The Burnett lab is focused on developing gene- and RNA-based therapies for human diseases.  Our recent work includes the development of RNA aptamers as targeted therapeutics and diagnostics for HIV and cancer.  The lab also specializes in genome editing strategies for generating HIV-resistant immune cells.  Dr. Burnett received his doctoral degree in Chemical and Biomolecular Engineering from the University of California, Berkeley, where he was co-advised by Profs. David Schaffer and Adam Arkin.  He first joined the City of Hope as a postdoctoral fellow in Dr. John Rossi’s laboratory.

Sreerupa Challa

Sreerupa Challa
Principal Scientist
Spring Bank Pharmaceuticals, Inc
Sreerupa Challa
Principal Scientist
Spring Bank Pharmaceuticals, Inc
 
About Speaker:

I am a team-orientated scientist with substantial experience in integrating inter-disciplinary knowledge to help advance drug development programs. My professional goals include a strong commitment to drug development through my diverse scientific background that includes oncology, immunology, immune signaling, molecular biology, virology and biochemistry. My experience spans from in vitro assays to in vivo modeling to support small molecule and biologic drug discovery development. Currently, I am a Principal Scientist at Spring Bank Pharmaceuticals successfully contributing to the progress of Anti-viral, Oncology and Inflammation programs at all stages. 

Rachel Fearns

Rachel Fearns
Associate Professor, Microbiology
Boston University
Rachel Fearns
Associate Professor, Microbiology
Boston University
 
About Speaker:

Dr. Fearns obtained her Ph.D. at the University of St Andrews, UK and performed post-doctoral training at the National Institutes of Health, USA studying factors that affect respiratory syncytial virus (RSV) transcription and genome replication. As a principal investigator, Dr. Fearns has worked to understand the molecular mechanisms by which the RSV polymerase functions, using a combination of cell-based and in vitro assays, and to determine the mechanisms of action of viral polymerase inhibitors.

Bruce Given

Bruce Given
COO, Head of R&D
Arrowhead Pharmaceuticals
Bruce Given
COO, Head of R&D
Arrowhead Pharmaceuticals
 
About Speaker:

Dr. Given has served as COO of Arrowhead Pharmaceuticals since 2011. Dr. Given retired as Chairman of the Board for ICON, plc in 2013 and served as President and Chief Executive Officer and as a member of the Board of Directors of Encysive Pharmaceuticals. Prior to joining Encysive, he was with Johnson & Johnson for 9 years, serving in several capacities including as President, International, Ortho-Clinical Diagnostics and as Head of U.S. Marketing & Sales and Research & Development for Janssen Pharmaceutica. Prior to entering the pharmaceutical industry, he was on the medical faculty at the University of Chicago. Dr. Given received his M.D. degree with honors from the University of Chicago, Pritzker School of Medicine and completed his medical training at the University of Chicago and at Brigham and Women’s Hospital, where he was Clinical Fellow at Harvard Medical School.

Kris Iyer

Kris Iyer
Co-Founder, Chief Scientific Officer
Spring Bank Pharmaceuticals
Kris Iyer
Co-Founder, Chief Scientific Officer
Spring Bank Pharmaceuticals
 
About Speaker:

R. P. Iyer, (Kris) is the co-founder and Chief Scientific Officer of Spring Bank Pharmaceuticals. He has more than 25 years’ experience in drug discovery in diverse therapeutic areas including antivirals, inflammation and immune-oncology. Kris is an innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences with over 100 publications and 150 issued and filed US and international patents. Prior to Spring Bank, Kris was the co-founder and VP of Discovery of Origenix Technologies.

Mamuka Kvaratskhelia

Mamuka Kvaratskhelia
Professor
Ohio State University
Mamuka Kvaratskhelia
Professor
Ohio State University
 
About Speaker:

Originally from the country of Georgia, Dr. Kvaratskhelia trained at Moscow State University, Russia; John Innes Center, England; University of Dundee, Scotland; and with Dr. Stuart Le Grice at Drug Resistance Program, NCI-Frederick, USA before starting his own program at the Ohio State University. Through his PhD and postdoctoral years Dr. Kvaratskhelia has been trained as a biochemist with a strong emphasis on studying protein-protein and protein-nucleic acid interactions. Since the beginning of his independent research career at the Ohio State University in 2003, his primary research focus has been to better understand the structure and function of HIV-1 integrase as a therapeutic target. He has developed extensive expertise in understanding retroviral integrases: their catalytic role in the virus life cycle, integration site selection in host cell chromosomes, and interactions with cognate cellular cofactors such as LEDGF/p75 and BET proteins (Sharma et al, 2013, PNAS). Particularly noteworthy is the recent discovery of a novel, non-catalytic function of integrase in HIV-1 biology as it binds the viral RNA genome to promote virion morphogenesis (Kessl et al, 2016, Cell). Another major area of focus of Dr. Kvaratskhelia’s research is the development of allosteric integrase inhibitors (ALLINIs). Toward this goal, his research team and collaborators have made critical contributions by elucidating the mechanism of action of currently available ALLINIs (Jurado et al, 2013, PNAS; Sharma et al, 2014, PLoS Pathog.), which are now in clinical trials. His current efforts are focused on developing novel, improved ALLINIs with entirely new scaffolds for their potential clinical application in treating AIDS patients.

Katharine Manson

Katharine Manson
Director, Regulatory Affairs
Intrinsik Corp.
Katharine Manson
Director, Regulatory Affairs
Intrinsik Corp.
 
About Speaker:

Katharine Manson is the Director of Regulatory Affairs at Intrinsik Corp. Ms. Manson, who holds a post-graduate certificate in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College, has been a consultant to the biotechnology industry in pharmaceutical and healthcare since 2003.

Ms. Manson works with a wide variety of clients to assist with product development goals. She does this by creating strategic product development plans aimed to meet scientific, regulatory and business needs, planning and coordinating submissions, and identifying and pre-empting regulatory issues. Her focus is on North American regulatory affairs, with particular knowledge of the regulatory aspects of U.S. pharmaceutical product development, and she has extensive experience with multiple pharmaceutical applications including NDS, CTA, NDA, and IND. Her proficiency encompasses both small molecule and biologic compound applications.

Ms. Manson serves with the Canadian Association of Pharmaceutical Regulatory Affairs (CAPRA) as the Toronto Dinner Meeting Chair. She is also a member of the Regulatory Affairs Professional Society (RAPS), the Drug Information Association (DIA), and the Pharmaceutical Sciences Group (PSG). She has contributed to various pharmaceutical industry workshops, co-authored a paper for the Canadian association of Professional Regulatory Affairs, and has been a contributing editor for RAPS Fundamentals of Canadian Regulatory Affairs.

Stephan Menne

Stephan Menne
Associate Professor, Microbiology & Immunology
Georgetown University
Stephan Menne
Associate Professor, Microbiology & Immunology
Georgetown University
 
About Speaker:

Stephan Menne received his Ph.D. in Virology and Immunology at the University of Duisburg-Essen in Germany, where his research concentrated on the immunopathogenesis of hepatitis B virus (HBV) using woodchucks and woodchuck hepatitis virus as a surrogate animal model. He completed a postdoctoral fellowship at Cornell University (Ithaca, NY) and was appointed thereafter to Assistant Professor. During that time he extended his studies and became involved in the testing of the safety, efficacy and innate and adaptive immune responses mediated by experimental drugs against HBV in woodchucks. Following his appointment to Associate Professor at Georgetown University Medical Center (Washington, DC) in 2010, he is now responsible for the testing of new HBV therapeutics in woodchucks that is funded by the Division of Microbiology and Infectious Diseases (DMID) of NIAID/NIH. This program is attempting to improve the treatment of chronic HBV infection and associated liver diseases, and is accessible to pharmaceutical companies and academic groups. His research is further funded by R01 grants and research agreements/contracts with pharmaceutical companies. He has published 55 peer-reviewed papers, 4 book chapters, and numerous conference abstracts.

Tara Strutt

Tara Strutt
Assistant Professor
University of Central Florida
Tara Strutt
Assistant Professor
University of Central Florida
 
About Speaker:

Tara Strutt, Ph.D. is an Assistant Professor in the Immunity and Pathogenesis Division of the Burnett School of Biomedical Sciences at the University of Central Florida. Her research is centered on understanding how the adaptive immune system controls innate inflammatory responses.

Kelly Warfield

Kelly Warfield
Senior Director, Antiviral Research and Development
Emergent BioSolutions
Kelly Warfield
Senior Director, Antiviral Research and Development
Emergent BioSolutions
 
About Speaker:

Dr. Kelly Lyn Warfield received her college degree from Loyola University, Maryland and Ph.D. degree in molecular virology from Baylor College of Medicine in Houston, Texas studying immune responses, pathogenesis and adverse events related to rotavirus vaccination and infection. During a National Research Council postdoctoral fellowship at the USAMRIID, Dr. Warfield developed animal models, vaccines and therapeutics for filoviruses. Dr. Warfield co-founded the start-up company Integrated Biotherapeutics, Inc. and was the Vice President of Vaccine Development for 6 years with a focus on development of antivirals and vaccines for Ebola and Marburg viruses. Currently, she is the Senior Director of Antiviral Research at Emergent BioSolutions with responsibility for the development activities for broad-spectrum antiviral and antibacterial compounds.

 

James Whitney

James Whitney
Assistant Professor
Beth Israel Deaconess Medical Center; Harvard University
James Whitney
Assistant Professor
Beth Israel Deaconess Medical Center; Harvard University
 
About Speaker:

Dr. James B. Whitney received his Ph.D. in Virology from McGill University in Montreal, Canada. He did his post-doctoral training at The Beth Israel Deaconess Medical Center and Harvard Medical School where he studied viral transmission and evolutionary dynamics in the setting of T cell vaccination. He is the Principal Investigator of the Viral Dynamics laboratory at the Center for Virology and Vaccine Research at the BIDMC.

His laboratory focuses on viral dynamics, emerging viral diseases and eradication strategies for the the HIV-1/SIV viral reservoir. In collaboration with Industry partners, he is evaluating a number of pre-clinical therapeutic modalities to reduce the HIV-1 reservoir burden and impact Zika infection.

Vaccines Research & Development 2017
KEYNOTE SPEAKERS
Kathrin Jansen

Kathrin Jansen
SVP and Head of Vaccine Research & Development
Pfizer
Kathrin Jansen
SVP and Head of Vaccine Research & Development
Pfizer
 
About Speaker:

Kathrin U. Jansen, Ph.D. is a Senior Vice President at Pfizer’s Pearl River, NY campus. Dr. Jansen has responsibility for the scientific management of vaccine research and early development as well as management responsibilities for all vaccines clinical and diagnostic testing.

Dr. Jansen received her doctoral degree in Microbiology, Biochemistry & Genetics from Phillips Universitat, Marburg, Germany, in 1984. Following completion of her formal training and postdoctoral work at the Institute for Mikrobiologie in Marburg, Dr. Jansen continued her training with Professor G.P. Hess at Cornell University working on the expression of the acetylcholine receptor in yeast for structural and functional studies. She then joined the Glaxo Institute for Molecular Biology in Geneva, Switzerland where she focused on basic studies of a receptor believed to be a drug target to treat allergies.

In 1992, Dr. Jansen moved to the Merck Research Laboratories. During the following 12 years, she directed a number of vaccine research efforts, including Merck’s novel bacterial vaccine programs. Dr. Jansen initiated Merck’s vaccine program for the prevention of human papillomavirus infection (HPV). She played a central role in the vaccine’s design, the development of novel HPV clinical diagnostic assays, clinical trial designs, the study of the virus’ epidemiology, the successful completion of the vaccine’s proof-of-concept trial and the entry of the vaccine into phase 2/3 clinical trials. Her efforts led to the licensure of the world’s first cervical cancer vaccine (Gardasil®).

Dr. Jansen left Merck in October 2004 to join VaxGen as Chief Scientific Officer and Senior Vice President for Research and Development with responsibility for VaxGen’s late stage development anthrax and smallpox vaccine programs.

In 2006, Dr. Jansen joined Wyeth (now Pfizer) as a Senior Vice President to lead the vaccine research (with focus on infectious disease targets), early development and clinical testing groups. In this capacity, she and colleagues at Pfizer supported the licensure of Prevnar 13 (infant indication), licensure application of Prevnar 13 (adult indication), as well as the conduct of the CAPITA trial. In addition, the work of her group and colleagues at Pfizer led to the successful outcomes of the proof-of-concept phase 2 clinical evaluation of the Neisseria meningitidis serogroup B vaccine and phase 1 trial for Staphylococcus aureus.

Dr. Jansen was appointed an Adjunct Professor at the University of Pennsylvania – School of Medicine in 2010. Dr. Jansen brings a recognized series of accomplishments, as well as an established international reputation in vaccine discovery research and development

DISTINGUISHED SPEAKERS
Rajendar Deora

Rajendar Deora
Assistant Professor, Microbiology & Immunology
Wake Forest School of Medicine
Rajendar Deora
Assistant Professor, Microbiology & Immunology
Wake Forest School of Medicine
 
About Speaker:

Dr. Deora received a M.Sc. degree in Biochemistry from the University of Calcutta. He graduated from the University of Illinois at Chicago in with a Ph.D. in Microbiology. Dr. Deora joined WFUHS as an Assistant professor in 2003 and was promoted to Associate Professor in 2010.
His areas of interest are: Virulence mechanisms of Bacterial pathogens; Molecular determinants of pathogenesis and Biofilm development; Host pathogen interactions, Effectiveness of small molecules on the colonization of and biofilm formation in the murine respiratory tract, Vaccine Development.

Cheryl Keech

Cheryl Keech
Executive Medical Director, Global Product Development
Pharmaceutical Product Development
Cheryl Keech
Executive Medical Director, Global Product Development
Pharmaceutical Product Development
 
About Speaker:

Dr. Keech is the Executive Medical Director for Infectious Diseases in the PPD Global Product Development group. Prior to working with PPD, Dr. Keech worked at PATH from 2012-2015. While at PATH, Dr. Keech served as global director of clinical and regulatory for the division of vaccine access and delivery (2015-2016) and global clinical lead for pneumococcal, influenza and respiratory syncytial virus programs (2012-2015). In her role as global director, she was responsible for the oversight of post licensure trials (PASS, phase IIIb/IV and real world effectiveness), disease surveillance activities, label extensions, pharmacovigilance, WHO prequalification submissions, health technology assessment, and risk evaluations and mitigation strategies. Dr. Keech also served as the Director/clinical lead for the Meningitis A Vaccine and clinical lead for the RTS,S Malaria Vaccine Initiative. Responsibilities of a clinical lead include establishing/optimizing the clinical development plan, trial design and protocol development, Trial execution, data analysis and reporting. During her time at PATH she was focused on programmes for Meningitis A, Malaria, Japanese Encephalitis, Pertussis, Rotavirus, Pneumoccoccus, RSV and influenza. Prior to PATH, Dr. Cheryl was the Sr. Director for R&D and Medical Affairs, GSK Australia Vaccine Unit, responsible for the oversight of phase I-IV trials (pediatric, adult and travelers) which included 16 licensed products and 6 products in various stages of development within the Australian Affliate. She has gained experience across the global (southeast Asia, Africa, EU, USA, Australia), across the phases of R&D (I-IV) and across all levels of World Bank defined country income (high, middle, low).  She has knowledge of national regulatory needs, global endorsement/recommendation processes (WHO prequalification, GAVCS recommendation) and the value proposition requirements for commercialization of new vaccine candidates (including national tendering and Minister of Health endorsement).  

Anders Lilja

Anders Lilja
VP Technical Development
Hookipa Biotech
Anders Lilja
VP Technical Development
Hookipa Biotech
 
About Speaker:

Dr. Anders Lilja is the VP of Technical Development at Hookipa Biotech AG and is responsible for developing promising product candidates from research to manufacturing. He led the preclinical characterization and manufacturing of Hookipa’s cytomegalovirus vaccine candidate HB-101. Prior to joining Hookipa, he was a Research Investigator and Associate Research Project Leader at Novartis Vaccines. Dr. Lilja holds an MSc in chemical engineering from Chalmers University of Technology (Sweden), a PhD in biochemistry from University of Maryland, and did postdoctoral training in molecular virology at Princeton University. He has co-authored several publications characterizing key cytomegalovirus vaccine antigens.

Janet McElhaney

Janet McElhaney
VP Research and Scientific Director
Health Sciences North Research Institute
Janet McElhaney
VP Research and Scientific Director
Health Sciences North Research Institute
 
About Speaker:

Janet E. McElhaney, MD, FRCPC, FACP, is HSN Volunteer Association Chair in Healthy Aging, VP Research and Scientific Director, Health Sciences North Research Institute, and Professor, Northern Ontario School of Medicine.

Her “Vaccine Initiative to Add Life to Years” (VITALiTY), is an interdisciplinary approach using measures of frailty to reflect overall health status and risk factors for catastrophic disability; developing biomarkers of protection against influenza and herpes zoster and exploring the contribution of “inflammaging” in designing new vaccines for improved protection in older adults.

The overall goal is to promote healthy aging through vaccination and to address the challenges of multiple chronic conditions particularly in rural and remote communities in Canada, including Indigenous people and their communities.

Kai McKinstry

Kai McKinstry
Assistant Professor
University of Central Florida
Kai McKinstry
Assistant Professor
University of Central Florida
 
About Speaker:
  1. Kai McKinstry received his PhD from the University of Saskatchewan (Canada) in 2005. He then undertook postdoctoral studies at the Trudeau Institute in the Adirondack Mountains of New York State focusing on understanding how memory T cells form and how their responses upon rechallenge differ from those of naïve T cells. Dr. McKinstry joined the Faculty of the Department of Pathology at the University of Massachusetts Medical School in 2005. Here he continued to research how protective memory T cells contribute to successful immune responses, and how specialized populations of memory T cells with different functions form. In 2015 Dr. McKinstry joined the Division of Immunity and Pathogenesis in the Burnett School of Biomedical Sciences at the University of Central Florida where his research is focused on understanding how memory T cells that reside at sites of infection are generated following infection and vaccination.
Matthew Memoli

Matthew Memoli
Director, LID Clinical Studies Unit, Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases
NIAID, NIH
Matthew Memoli
Director, LID Clinical Studies Unit, Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases
NIAID, NIH
 
About Speaker:

Dr. Memoli is a graduate of he College of William and Mary and he received his Masters Degree in Microbiology from Thomas Jefferson University in Philadelphia, PA.  He then received his MD from St George’s University School of Medicine.  He completed a residency in internal medicine at the Washington Hospital Center Georgetown University Internal Medicine Program in Washington, DC.    After completing an infectious disease fellowship in NIAID at the National Institutes of Health, Dr. Memoli developed a clinical/translational research program to study influenza and other respiratory viruses in the Laboratory of Infectious Diseases.  He now serves as the Director of the LID Clinical Studies Unit.

Dr. Memoli has taken part in the research response for multiple emerging infectious diseases including pandemic influenza, Ebola, and Zika. He has reinvigorated the healthy volunteer influenza challenge model in the US and it serves as his main research interest.   He also has undertaken the first clinical trial involving a mosquito saliva based vaccine, and is highly interested in novel and uniquely designed clinical trials.  Other interests include clinical pathogenesis of viral infections in immunocompromised patients and other special at risk populations, intrahost evolution of influenza, antiviral resistance, immune correlates of protection against respiratory viruses, modes of transmission, and molecular diagnostics.

James Moon

James Moon
Assistant Professor, Biomedical Engineering; Co-Founder & Chief Science Officer
University of Michigan; EVOQ Therapeutics
James Moon
Assistant Professor, Biomedical Engineering; Co-Founder & Chief Science Officer
University of Michigan; EVOQ Therapeutics
 
About Speaker:

Dr. James Moon is John Gideon Searle Assistant Professor in the Department of Pharmaceutical Sciences and Biomedical Engineering at the University of Michigan, Ann Arbor. Dr. Moon is also a co-founder and Chief Science Officer of EVOQ Therapeutics that works on cancer vaccine technologies. Dr. Moon’s translational research program aims to develop novel engineering tools for improving vaccines and immunotherapies. He has received numerous awards, including 2016 National Science Foundation CAREER Award, 2016 DOD-CDMRP Career Development Award, 2015 Melanoma Research Alliance Young Investigator Award, the 2012 NIAID Research Scholar Development Award, and the 2011 IEEE-EMBS Harvard Wyss Institute Award for Translational Research. Dr. Moon received his bachelor’s degree from the University of California, Berkeley, and his Ph.D. from Rice University, and he completed his postdoctoral training at MIT (HHMI).

Mark Poznansky

Mark Poznansky
Director, Vaccine and Immunotherapy Center
Massachusetts General Hospital
Mark Poznansky
Director, Vaccine and Immunotherapy Center
Massachusetts General Hospital
 
About Speaker:

Dr. Mark C. Poznansky, MD, PhD.
Director, Vaccine and Immunotherapy Center, Massachusetts General Hospital.

Dr. Poznansky is Associate Professor of Medicine at Harvard Medical School and Attending Physician in Infectious Diseases Medicine and Director of the Vaccine and Immunotherapy Center (VIC) at MGH. He is the discoverer of fugetaxis, the principle of immuno-repulsion that forms the basis of the company’s products. His laboratory defines molecular mechanisms for novel immune processes and explores the relevance of these mechanisms to novel approaches to vaccines and immunotherapies for cancer, infectious diseases and diabetes.

Dr. Poznansky obtained his B.Sc. and his MD at the University of Edinburgh in the United Kingdom and his PhD from the Department of Medical Sciences at Cambridge University. He also served as a Resident in Clinical Immunology at the Addenbrooke’s Hospital in Cambridge, UK and a Captain in the Royal Army Medical Corps. Following post-doctoral research training in retrovirology at Harvard Medical School and the Dana Farber Cancer Institute, Dr. Poznansky did further residency training at St. Mary’s Hospital, Imperial College, London.. He then returned to Harvard Medical School as a Clinical Fellow in the Infectious Diseases Fellowship Training Program, and has been progressively promoted to his current position. He has been awarded a prestigious MGH Research Scholar Award, and was recognized in 2015 by the MGH Cancer Center One Hundred event for his contributions to the development of novel immunotherapies and vaccines for cancer.

In the years following his faculty appointment, Dr. Poznansky has gained very well deserved recognition as a leader in the field of leukocyte migration and the modulation of leukocyte trafficking and function for the purposes of the development of novel vaccines and immunotherapies for infectious diseases, cancer and type 1 diabetes. He has also gained a particular recognition for establishing a new model for translational research that accelerates the process by which basic biological discoveries move towards products and technologies that improve patient care and treatment. His work on novel cancer vaccines and immunotherapies are predominantly focused on treating mesothelioma and ovarian cancer – two very difficult to treat diseases. Dr. Poznansky’s team at VIC is currently developing both a small molecule modulator of the immune system and a fusion protein for this purpose in close collaboration with clinical scientists and industry experts. Dr. Poznansky also chairs the Boston Immunotherapy Initiative which is a deeply collaborative consortium of doctors and scientists from across academia in Boston who set as their mission the accelerated execution of trials of new immunotherapies for cancer including mesothelioma.

Alyson Smith

Alyson Smith
Assistant Research Professor; Director, Immunology
University of Montana; Inimmune Corp
Alyson Smith
Assistant Research Professor; Director, Immunology
University of Montana; Inimmune Corp
 
About Speaker:

Alyson Smith is an Assistant Research Professor at the University of Montana in the Division of Biological Sciences and also the Director of Immunology at the biotech startup Inimmune. She completed her PhD in molecular pharmacology at the Mayo Clinic in Rochester MN. She went to do post doctoral fellowships at both Mayo Clinic and GlaxoSmithKline Vaccines where she worked on understanding the structure-function relationships and mechanism of action of several classes of innate stimulating agonists.

Joshua Speidel

Joshua Speidel
Managing Director, Commercial Practice
Latham BioPharm Group
Joshua Speidel
Managing Director, Commercial Practice
Latham BioPharm Group
 
About Speaker:

Dr. Speidel leads the development and execution of a Commercial Practice at LBG that provides subject matter expertise and advisory services to mergers and acquisition, strategic business development, biological product development and due diligence to clients. Dr. Speidel is a biotechnology product development professional with experience from pre-discovery to the lifecycle management of mature products destined for the HHS Pandemic Influenza Vaccine Stockpile. Dr Speidel provides program management, federal contract compliance support, and technical expertise to clients. He has led teams in the submission of proposals resulting in >$89M of awards. As a Health Scientist for the U.S. Department of Health and Human Services (HHS), Biomedical Research and Development Authority (BARDA), he led efforts to establish the core capabilities to support the licensure of medical countermeasures in the areas of manufacturing capacity, product development, clinical studies, and long-term stockpiling. At BARDA, Dr. Speidel was responsible for the post-licensure management of three pandemic influenza vaccine stockpile programs, one advanced development program for a licensed recombinant influenza vaccine, and the Clinical Studies Network program. The total contract values of these efforts were in excess of $17 billion. Earlier, while consulting to the U.S. Defense Advanced Research Projects Agency (DARPA), Dr. Speidel created programmatic concepts that were pitched to DARPA’s director and resulted in excess of $250M in contract awards, was the technical point of contact for two teams in the “Accelerated Manufacturing of Pharmaceuticals” program which pioneered efforts in recombinant vaccine production, and was the project manager for their $100M response to the H1N1 pandemic that built three tobacco based manufacturing facilities and advanced a pre-discovery stage vaccine candidate through a Phase 1 Clinical Trial, on time and on budget.

Naveen Surendran

Naveen Surendran
Research Scientist II
Rochester General Hospital Research Institute
Naveen Surendran
Research Scientist II
Rochester General Hospital Research Institute
 
About Speaker:

Dr. Surendran’s research focuses on the human innate immune regulation of adaptive immunity against neonatal and pediatric infectious diseases. His doctorate was in Immunology and Microbiology with a specific focus on dendritic cell (DC) biology and vaccine development. During his post-doctoral fellowship at the Institute of Human Virology, University of Maryland he studied the three way interactions between dendritic cells, natural killer cells and γδ- T cells and DC mediated T-follicular helper cell generation and its critical role in inducing long term B cell memory responses. As a Research Scientist at RGHRI, Dr. Surendran is studying innate immunity and responses to vaccines in newborns and infants. Early immunization is required to protect infants but is limited by the immaturity of the immune system. In the short-term Dr. Surendran’s goal is to devise novel methods to safely improve the efficacy of poorly immunogenic vaccines by use of better adjuvants or TLR agonist combinations and in the long-term he focuses on delineating the basic mechanisms of innate regulation of adaptive immunity in neonates/infants to develop new vaccines against infectious diseases that lack (ex. RSV) effective vaccines. Dr. Surendran seeks to elucidate the exact nature of signals required to induce neonatal/infant APCs to effectively stimulate adaptive B and T cell responses.

Stephen Thomas

Stephen Thomas
Chief, Division of Infectious Diseases
State University of New York, Upstate Medical University
Stephen Thomas
Chief, Division of Infectious Diseases
State University of New York, Upstate Medical University
 
About Speaker:

Stephen J. Thomas, MD is an Infectious Diseases physician and Professor of Medicine who recently joined the State University of New York (SUNY) Upstate Medical University in Syracuse, NY. Prior to joining SUNY Upstate he retired as a Colonel (COL) in the U.S. Army Medical Corps. Dr. Thomas’s last position in the Army was as the Deputy Commander for Operations (Chief Operating Officer) at the Walter Reed Army Institute of Research (2014-2016). During his military career Dr. Thomas spent more than 5 years living and working in Southeast Asia coordinating field and vaccine research. He spent much of his early career working on dengue and other arboviruses and recently has had key involvement in Ebola, MERS-CoV, and Zika vaccine development efforts. Dr. Thomas has authored and more than 74 manuscripts and 7 book chapters. He routinely speaks on infectious diseases and research and development issues at national and international scientific events and sits on expert scientific committees, working groups, and advisory boards for the Department of Defense, the U.S. NIH, non-governmental organizations, foreign nation regulatory agencies, and numerous pharmaceutical companies exploring issues related to infectious diseases. He earned his Bachelor of Arts with Honors in Biomedical Ethics from Brown University, his Medical Degree from the Albany Medical College, and completed his internship and residency in Internal Medicine and Infectious Diseases fellowship at the Walter Reed Army Medical Center. Dr. Thomas is board certified in both specialties, holds a certification in Tropical Medicine and Traveler’s Health from the America Society of Tropical Medicine and Hygiene (ASTMH), and is a Fellow in the American College of Physicians, Infectious Diseases Society of American, and the ASTMH.

Jeffrey Ulmer

Jeffrey Ulmer
Head, Preclinical R&D US
GSK Vaccines
Jeffrey Ulmer
Head, Preclinical R&D US
GSK Vaccines
 
About Speaker:

Dr. Jeffrey Ulmer received his B.Sc. with honors from the Department of Chemistry at the University of Regina in 1978 and was the recipient of the Merit Award of the Society of Chemical Industry of Canada. He received his Ph.D. in biochemistry from McGill University in 1985 and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories, Chiron Corporation and Novartis Vaccines he conducted seminal studies on nucleic acid vaccines and novel vaccine adjuvants/delivery systems. He has published over 200 scientific articles, is on the editorial boards of Expert Opinion on Biological Therapy, Human Vaccines, and Expert Review of Vaccines. He is currently Head, Preclinical R&D, GSK Vaccines.

Robert Walker

Robert Walker
Director, Division of Clinical Development
BARDA, HHS
Robert Walker
Director, Division of Clinical Development
BARDA, HHS
 
About Speaker:

Dr. Walker is the (Acting) Chief Medical Officer and Director of the Division of Clinical Development (DCD) in the Biomedical Advancement Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The DCD manages the Clinical Studies Network and is responsible for oversight of the coordination, execution, and analysis of interventional clinical studies funded by BARDA. Dr. Walker joined BARDA in 2014, and oversees a diverse portfolio of projects. Prior to joining BARDA, Dr. Walker was chief medical officer at Nuron Biotech, vice president of clinical development at Aeras, and vice president of clinical development and medical and scientific affairs at MedImmune, Inc. Before working in biotech, Dr. Walker was a clinical investigator at the National Institute of Allergy and Infectious Diseases and an attending physician in Critical Care Medicine at the National Institutes of Health. 

Anti-Infectives Partnering & Deal-Making 2017
DISTINGUISHED SPEAKERS
Mark Albrecht

Mark Albrecht
Project Officer, Anti-Bacterials Branch
BARDA, HHS
Mark Albrecht
Project Officer, Anti-Bacterials Branch
BARDA, HHS
 
About Speaker:

Mark Albrecht, PhD joined the Biomedical Advanced Research and Development Authority (BARDA) in March 2012. As a BARDA project officer within the Anti-Bacterials Branch, he works across the PHEMCE to strengthen inter-agency collaborations, coordinate efforts to advance the development of bio-defense medical countermeasures, and ensure that agency portfolios are properly aligned. Dr. Albrecht leads multiple interdisciplinary teams focused on supporting the day-to-day advanced development and regulatory activities necessary to gain marketing approval of medical countermeasures addressing our nation’s bio-defense and public health needs. Prior to his arrival at BARDA, Dr. Albrecht was a Senior Staff Scientist at the Biological Defense Research Directorate (BDRD) within the Naval Medical Research Center (NMRC) were he was responsible for leading the Navy’s programs on passive immune-therapy against anthrax and the development of multi-valent/agent vaccination strategies against Bacillus anthracis and Yersinia pestis based on recombinant proteins and DNA. He also supported the Navy’s and DARPA’s Seven-Day Burkholderia Biodefense Research Program. In his roles at BARDA and BDRD Dr. Albrecht has facilitated and maintained numerous public-private partnerships between industry and Government organizations. Dr. Albrecht received his B.A. in Biology from the Whitman College, Walla Walla, WA. He went on to the University of California Riverside where he received his PhD in Microbiology while studying the properties of sensitivity and resistance of Pseudomonas aeruginosa and B. cepacia to antimicrobial peptides and the role of alginate lyase during P. aeruginosa biofilm formation.

Gregory Davenport

Gregory Davenport
Vice President
The Conafay Group
Gregory Davenport
Vice President
The Conafay Group
 
About Speaker:

Gregory J. Davenport, Ph.D. is a VP with The Conafay Group (TCG) - professional services firm that assists life sciences companies and organizations in securing federal non-dilutive funding, congressional and agency relationship building, alliance development and policy lobbying. At TCG, Greg assist various clients with partnering and securing funding from organizations such as HHS, BARDA and the Department of Defense.

Greg has over 22 years of experience in medical product development and government contracting. Prior to TCG, Greg held various C-Level executive positions with both private biotech and publically traded life science companies where he secured more than $350 million in government funding.

Greg earned a B.S. from Dillard University in New Orleans, received his Ph.D. in molecular biology from Howard University, and performed post-doctoral studies at the University of Maryland Medical Center and George Washington University Medical Center. Greg currently serves on the board of LouisianaBio (LA state affiliate of Biotechnology Industry Association); on the advisory board of the Mount Saint Mary’s University Biotechnology and Management Program; and serves on the advisory council for the Mount Opportunities for Success in Science (MOSS), a National Science Foundation S-STEM funded program.

Gregory Frank

Gregory Frank
Director, Infectious Disease Policy, Health Policy
Biotechnology Innovation Organization (BIO)
Gregory Frank
Director, Infectious Disease Policy, Health Policy
Biotechnology Innovation Organization (BIO)
 
About Speaker:

Greg comes from a research background of viral immunology, where he trained at the University of Pittsburgh and pursued his postdoctoral training at the National Institutes of Allergy & Infectious Diseases (NIAID). Greg began his science policy career first at the Federation of American Societies for Experimental Biology (FASEB) before joining the Infectious Diseases Society of America (IDSA), where he lead science and diagnostic policy. Greg joined the Biotechnology Innovation Organization (BIO) in 2016 where he leads several infectious diseases policy issues, including antimicrobial resistance.

Mark Goldberger

Mark Goldberger
Independent Consultant
Mark Goldberger MD MPH LLC
Mark Goldberger
Independent Consultant
Mark Goldberger MD MPH LLC
 
About Speaker:

Dr. Goldberger received his MD degree from the Columbia University College of Physicians and Surgeons in New York and his MPH from George Washington University in Washington, DC. He completed his postgraduate training at the Presbyterian Hospital in New York and the Centers for Disease Control (CDC) in Atlanta. He is board certified in internal medicine and infectious disease and is a fellow of the Infectious Diseases Society of America. Dr. Goldberger was on the faculty of Columbia University for nine years.

Dr. Goldberger joined the Food and Drug Administration in 1989. At FDA he served as primary reviewer, medical team leader, Director of the Division of Special Pathogen and Immunologic Drug Products and Director of the Office of Antimicrobial Products within the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA). In addition to these positions he coordinated drug shortage activities within the CDER from 1990 - 2006. Dr. Goldberger also was the FDA lead in an assessment of the readiness of the Pharmaceutical Industry for Y2K. In 2000 he spent 8 months as acting Associate Center Director for Quality Assurance in CDER during which time he developed the concept of the Regulatory Briefing. In 2003-2004 he was Acting Deputy Center Director of CDER. In 2006 he became Medical Director for Emerging and Pandemic Threat Preparedness within the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration.

In October 2007 he joined Abbott as Divisional Vice President – Regulatory Policy and Intelligence. In this role he was involved in multiple areas of both product and policy development. He continued in this position when AbbVie separated from Abbott until May 2013 when he became VP Regulatory Affairs and Senior Advisor. In this position he provided regulatory and scientific input both into multiple development programs and in the preparation of marketing applications. In September 2014 he retired from AbbVie and opened his own consulting practice as Mark Goldberger MD MPH LLC.

While at Abbott and AbbVie he participated in PhRMA and efpia working groups on antibiotic resistance and twice presented on this subject to the European Medicines Agency as well as to the FDA. As a member of the FDA Alumni Association he has participated in several training sessions for staff from CDE/CFDA as well as for CDE/TFDA. He has presented multiple times at DIA China as well as at APEC 2012 and 2016 in Taiwan.

Tina Guina

Tina Guina
Program Officer, Division of Microbiology and Infectious Diseases
NIAID, NIH
Tina Guina
Program Officer, Division of Microbiology and Infectious Diseases
NIAID, NIH
 
About Speaker:

Tina Guina, PhD
Program Officer, Drug Development Section, Office of Biodefense, Research Resources and Translational Research
NIAID, NIH

Tina Guina manages a portfolio of contracts for development of new anti-infective therapeutics, and collaborates with other federal agencies within the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) on policy and response strategies to biodefense and other infectious disease emergencies. She is a principal investigator of interagency Working Group for qualification of animal model of pneumonic tularemia as a Drug Development Tool.

Dr. Guina has twenty-five years of experience in infectious disease research, and nine years of experience in development of vaccines, therapeutics and animal models. Prior to joining NIAID in 2012, Dr. Guina worked in biotech industry on development of vaccines for tuberculosis, anthrax and influenza, with focus on product development and regulatory strategies. During her academic appointment at the University of Washington in Seattle in 2002-2008, she led research studies that characterized bacterial virulence factors and regulatory networks using state-of the art systems biology approaches. Dr. Guina holds a PhD in molecular biology and biochemistry from Wesleyan University and BSc in molecular biology from University of Zagreb, Croatia.

Matthew Hepburn

Matthew Hepburn
Program Manager, Biological Technologies Office
DARPA
Matthew Hepburn
Program Manager, Biological Technologies Office
DARPA
 
About Speaker:

COL Matthew Hepburn, MC, USA joined DARPA as a program manager in 2013. He aims to address the dynamic threats of emerging infectious diseases with potential impact on national security.

Prior to joining DARPA, COL Hepburn served as the Director of Medical Preparedness on the White House National Security Staff. Additional previous assignments include: Chief Medical Officer at a Level II medical facility in Iraq, clinical research director at the US Army Medical Research Institute for Infectious Diseases, exchange officer to the United Kingdom and internal medicine chief of residents at Brooke Army Medical Center at Fort Sam Houston, Texas. 

COL Hepburn completed internal medicine residency and infectious diseases fellowship programs at Brooke Army Medical Center. He holds Doctor of Medicine and Bachelor of Science in biomedical engineering degrees from Duke University.

Jonathan Kfoury

Jonathan Kfoury
Managing Director & Partner
L.E.K. Consulting
Jonathan Kfoury
Managing Director & Partner
L.E.K. Consulting
 
About Speaker:

Jonathan Kfoury is a Managing Director and Partner in L.E.K. Consulting’s San Francisco office, focused on biopharmaceuticals, medical technology, and life sciences. He joined the firm in 2006, and since that time has led an extensive set of engagements with global biopharmaceutical, medical technology, and diagnostic clients across human health, animal health, and agribusiness markets. Jonathan advises clients on commercial strategy and life-cycle management for in-line products, market access and commercialization planning for pipeline assets, and growth / partnering strategy. With an operating background in both Clinical and Business Development at specialty biopharmaceutical companies, Jonathan brings a hands-on understanding of internal decision-making needs to his advisory work with clients.

Jonathan has published and spoken-widely on the subject of antimicrobial resistance in human and animal health, including on key business issues and opportunities facing biopharmaceutical manufacturers and other stakeholders.

In addition to significant experience in immunology, oncology, men's/women's health, and CNS/pain management, Jonathan’s interests include growth strategy across infectious-diseases, biosimilars, and outcomes-driven digital health opportunities.

Prior to joining L.E.K., Jonathan was a Business Development executive for Acusphere and Purdue Pharma, and manager of global Clinical Development for Cubist Pharmaceuticals’ (now Merck) blockbuster antibiotic Cubicin® - the most successful IV antibiotic launched in US history. In addition to global management training at INSEAD, Jonathan earned an S.M. in Health Policy & Management from Harvard University, and graduated from Trinity College with a Bachelor of Science degree in Neuroscience.

Cristina Larkin

Cristina Larkin
Chief Commercial Officer
Spero Therapeutics
Cristina Larkin
Chief Commercial Officer
Spero Therapeutics
 
About Speaker:

Cristina Larkin is the Chief Commercial Officer at Spero Therapeutics in Cambridge, MA. Ms. Larkin has over 22 years of experience developing strategic commercial insights for biopharmaceutical companies and their infectious disease products such as Avycaz, Dalvance, Teflaro, Levaquin and Floxin. Prior to joining Spero, she served as Assistant Vice President for Actavis, formerly Forest Laboratories. During that time, Ms. Larkin led the commercial hospital antibiotic franchise team and was responsible for the US launch and execution strategy for several antibiotics. Additionally, she was a member of the business assessments and business development team and played an integral role in the out-licensing of ceftaroline to AstraZeneca, the acquisition of Durata and more.

Ms. Larkin received a bachelor’s degree from Florida State University.

David McAdams

David McAdams
Professor, Business Administration & Economics
Duke Fuqua School of Business
David McAdams
Professor, Business Administration & Economics
Duke Fuqua School of Business
 
About Speaker:

David McAdams is Professor of Business Administration at the Fuqua School of Business, Duke University. He is also Professor of Economics in the Economics Department at Duke. He earned a B.S. in Applied Mathematics at Harvard University, an M.S. in Statistics from Stanford University, and a Ph.D. in Business from the Stanford Graduate School of Business. Before joining the faculty at Duke, he was Associate Professor of Applied Economics at the MIT Sloan School of Management.

Professor McAdams' primary research interests are microeconomic theory and game theory. His work has been published in leading economics journals, on a range of topics including auctions, pricing, negotiations, and relationships. His most recent work develops the economic theory of infectious-disease diagnosis and management, with implications for antibiotic resistance and investment.

Aaron Pelta

Aaron Pelta
Vice President, Business Development & Commercial Strategy
Arsanis, Inc.
Aaron Pelta
Vice President, Business Development & Commercial Strategy
Arsanis, Inc.
 
About Speaker:

Aaron Pelta has been Vice President, Business Development & Commercial Strategy at Arsanis, Inc since 2016. Prior to Arsanis, Aaron served in a variety of Business Development and Commercial roles in over 10 years at Cubist Pharmaceuticals, Aaron led the execution of several anti-infective deals during his time at Cubist, including the acquisitions of Optimer and Calixa. Aaron also worked in Business Development roles at Shire and AMAG.

Danielle Peters

Danielle Peters
President
Magnet Strategy Group
Danielle Peters
President
Magnet Strategy Group
 
About Speaker:

Danielle Peters is President of Magnet Strategy Group, a public affairs consulting firm operating in the United States and Canada. Magnet maintains an extensive roster of specialized consultants and partners in both countries, to provide clients with a customized public affairs team focused on achieving results.

Prior to founding Magnet Strategy Group, Dani held senior roles with public affairs firms in Washington, D.C. and Ottawa, Ontario, concentrating on fields that include innovation, healthcare and life sciences. Over the past decade, Dani has worked closely with industry, not-for-profit and government on advocacy, public policy and funding strategies in the health sector. In addition to operating Magnet Strategy Group, Dani serves on the Industry Advisory Board for Bloom Burton & Co., a healthcare investment advisory firm in Toronto, Canada.

Michael Pucci

Michael Pucci
Executive Director, Early Drug Discovery
Spero Therapeutics
Michael Pucci
Executive Director, Early Drug Discovery
Spero Therapeutics
 
About Speaker:

Michael J. Pucci, PhD, is Executive Director, Early Drug Discovery, at Spero Therapeutics in Cambridge, MA. He has more than 28 years of experience in antibacterial drug discovery and has previously held positions at Achillion Pharmaceuticals, Bristol-Myers Squibb Co., and in R&D at Microlife Technics/Unilever. At BMS, he worked on several cephalosporin projects providing penicillin-binding protein (PBP) binding data analyses for candidate compounds and leading one program through pre-clinical development. He also was involved with identifying novel antibacterial targets and developing high-throughput screens to identify inhibitors while leading the initial bacterial genomics effort at BMS.  At Achillion, he led novel topoisomerase inhibitor programs as well as a collaborative carbapenem project. Dr. Pucci is co-founder and currently employed at Spero Therapeutics, a biotech company whose goal is to develop novel therapies to treat antibiotic-resistant bacterial infections. He is a member of the American Society for Microbiology and serves on the Editorial Boards of Antimicrobial Agents and Chemotherapy, Microbial Drug Resistance, and the Annals of the New York Academy of Sciences. He has participated in numerous NIH review panels including the Drug Discovery and Resistance (DDR) Study Section. He is an author on more than 80 publications and 17 patents. Dr. Pucci received his B.S. in Biology from the University of Connecticut, his Ph.D. in Microbiology from Temple University, and had post-doctoral training at Virginia Commonwealth University.

Marina Santiago

Marina Santiago
Research Scientist & Infectious Disease Lead
Finch Therapeutics
Marina Santiago
Research Scientist & Infectious Disease Lead
Finch Therapeutics
 
About Speaker:

Marina Santiago joined Finch Therapeutics in July 2016 to help drive Finch's programs targeting drug resistant infections. For the last 10 years, Dr. Santiago has worked on different aspects of antibiotic resistance, from natural product discovery and isolation, to developing genomics techniques for identifying new resistance factors. She received her BS in Molecular Biophysics and Biochemistry from Yale University, and her PhD in Chemical Biology at Harvard Medical School.

Kimberly Sciarretta

Kimberly Sciarretta
Interdisciplinary Scientist/Project Officer
BARDA, HHS
Kimberly Sciarretta
Interdisciplinary Scientist/Project Officer
BARDA, HHS
 
About Speaker:

Kimberly Sciarretta is a Project Officer with the Anti-Infectives Program the in the Division of CBRN Countermeasures at the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Dr. Sciarretta joined BARDA in February 2015 as an Interdisciplinary Scientist and is a Project Officer for several therapeutic medical countermeasure programs. Prior to BARDA, Dr. Sciarretta consulted as a subject matter expert to several Federal Agencies.

Jeffrey Stein

Jeffrey Stein
President and Chief Executive Officer
Cidara Therapeutics
Jeffrey Stein
President and Chief Executive Officer
Cidara Therapeutics
 
About Speaker:

Jeffrey Stein, Ph.D., has been the President and Chief Executive Officer of Cidara Therapeutics since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September of 2013. Dr. Stein was also the founding Chairman and President of the Antibiotics Working Group. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at UCSD.

Joe Thomas

Joe Thomas
Associate, Antibiotic Resistance Project
The Pew Charitable Trusts
Joe Thomas
Associate, Antibiotic Resistance Project
The Pew Charitable Trusts
 
About Speaker:

Joe Thomas is an associate on the Pew Charitable Trusts’ antibiotic resistance project. Joe works on research and polices to help spur the discovery and development of urgently needed antibiotics. Prior to Pew, he worked at the London School of Economics and Political Science (LSE) on identifying barriers to development in the market for rapid diagnostic devices for bacterial infections. He has bachelor’s degrees in biology and political science from the University of Pittsburgh and an MSc from the London School of Economics and Political Science.

Andrew Thorrens

Andrew Thorrens
‎Reimbursement & Market Access Executive
Allergan
Andrew Thorrens
‎Reimbursement & Market Access Executive
Allergan
 
About Speaker:

Andrew Thorrens is the Head of Market Access and Reimbursement Strategy for Allergan. Andrew has a distinctive career with over 20 years of diversified leadership experience in the healthcare industry. His experience with claims adjudication management, employee benefits, pricing and reimbursement strategy in the biopharmaceutical industry brings well-rounded expertise in market access to the anti-infective commercial team at Allergan.

Andrew joined Allergan through the acquisition of Durata Therapeutics, Inc., where he also headed the market access and reimbursement for Dalvance in its initial launch. prior to Durata, Andrew led the health policy and reimbursement strategy for Takeda Pharmaceuticals and previous to that spent 18 years at Baxter International, Inc., where he managed the employee health and welfare plans and instituted a company wide reimbursement strategy and payor relations function.

Andrew has a deep understanding of the evolving payment methodologies and health policy initiatives stemming from the Affordable Care Act in the public and commercial payer sector including Medicare Part B drug reimbursement proposals. In his current role at Allergan he actively works at the intersection of health policy, health economics and reimbursement strategy, and, is a frequent speaker on these topics.

Christine Tkaczyk

Christine Tkaczyk
Senior Scientist, Infectious Diseases
MedImmune
Christine Tkaczyk
Senior Scientist, Infectious Diseases
MedImmune
 
About Speaker:

Christine Tkaczyk is currently a Senior Scientist at Medimmune. She developed several programs to identify specific human monoclonal antibodies as alternative therapies against bacterial infections especially Staphylococcus aureus. She earned a PhD in immunology from Pasteur Institute, Paris. She completed her postdoctoral training at the National Institutes of Health, NIAID.

Vu Truong

Vu Truong
Founder & Chief Executive Officer
Aridis Pharmaceuticals
Vu Truong
Founder & Chief Executive Officer
Aridis Pharmaceuticals
 
About Speaker:

Founder, Chief Executive Officer, and Director
Dr. Truong is a founder of Aridis and recently elected to the CEO position in 2014 after having served as the company's Chief Scientific Officer for the past 9 years. He has over 18 years of experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to Medimmune), and Medimmune (sold to Astra Zeneca). He has a life-long interest and research experience in infectious diseases, focusing on the development of innovative human monoclonal antibodies and vaccines designed to address life threatening infections. His product development experience includes FluMist™, Synagis™ mAb, and a number of other monoclonal antibody based therapeutics. Dr. Truong is the principal architect of the Aridis technologies, which includes a range of anti-infective products and pharmaceutical processing technologies. He received his Ph.D. in Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.

Adam Woodrow

Adam Woodrow
Vice President & Chief Commercial Officer
Paratek
Adam Woodrow
Vice President & Chief Commercial Officer
Paratek
 
About Speaker:

Adam Woodrow joined Paratek in October 2014 to lead the commercialization of Paratek’s product portfolio. Adam previously worked for Pfizer for five years in various strategic and operational commercial roles. While at Pfizer, Adam led the commercial development group in Pfizer's Specialty Care Business Unit, launching Xeljanz® for Rheumatoid Arthritis and Vyndaqel® for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). In addition, Adam led the global strategic marketing teams for a variety of products in fields ranging from rare disease to acute hospital based infections; major products included Enbrel®, Zyvox®, ReFacto® and Benefix®. Adam joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President and Global Business Manager for Enbrel leading all commercial aspects of Wyeth's inflammation portfolio, co-promotion, licensing, and product development. In his 10 years at Wyeth, Adam held senior marketing and sales positions in the US and in his native UK. During his career in the pharmaceutical industry, Adam has worked with several non-profit societies and organizations. Adam has a Bachelor of Science degree in Industrial Chemistry from the University of Wales College of Cardiff.